Gandhi C R, Sproat L A, Subbotin V M
Department of Anesthesiology/Critical Care Medicine, University of Pittsburgh, Pennsylvania, USA.
Life Sci. 1996;58(1):55-62. doi: 10.1016/0024-3205(95)02255-4.
Endothelin-1 (ET-1), the most powerful agent to cause constriction of the hepatic vasculature, is synthesized in the liver by sinusoidal endothelial cells. Circulating ET-1 levels have been shown to increase in liver cirrhosis. As liver could be a major source of increased plasma ET-1 as well as a target for its pathologic actions, this study was designed to determine hepatic ET-1 and ET receptor(s) in experimental liver cirrhosis. Cirrhosis was induced in rats by intraperitoneal administration of carbon tetrachloride for 8 weeks. Hepatic ET-1 was measured by radioimmunoassay and ET receptors were determined by radioligand competition binding procedure. A four fold increase in ET-1 concentration accompanied by a 65% increase in ET-receptor density was observed in the cirrhotic liver. There was no change in the ET receptor affinity. The capacity of the liver to metabolize ET-1 was reduced significantly in cirrhosis. Interestingly, transforming growth factor-beta, hepatic levels of which increase in cirrhosis, stimulated ET-1 synthesis in cultured Ito cells. It has been shown that ET-1 is a potent constrictor of Ito cells that proliferate and transform into highly contractile myofibroblasts in liver cirrhosis. Thus, interactions between ET-1 and Ito cells may have significant implications in the pathogenesis and complications of liver cirrhosis.
内皮素 -1(ET -1)是导致肝血管收缩的最强有力介质,由肝窦内皮细胞在肝脏中合成。肝硬化患者循环血中ET -1水平已被证实升高。由于肝脏可能是血浆ET -1升高的主要来源,也是其病理作用的靶器官,本研究旨在测定实验性肝硬化大鼠肝脏中的ET -1及ET受体。通过腹腔注射四氯化碳8周诱导大鼠肝硬化。采用放射免疫分析法测定肝脏ET -1水平,通过放射性配体竞争结合法测定ET受体。在肝硬化肝脏中观察到ET -1浓度增加了四倍,同时ET受体密度增加了65%。ET受体亲和力无变化。肝硬化时肝脏代谢ET -1的能力显著降低。有趣的是,肝硬化时肝脏中转化生长因子 -β水平升高,其可刺激培养的肝星状细胞合成ET -1。研究表明,ET -1是肝星状细胞的强效收缩剂,肝星状细胞在肝硬化时增殖并转化为高度收缩性的肌成纤维细胞。因此,ET -1与肝星状细胞之间的相互作用可能在肝硬化的发病机制及并发症中具有重要意义。